VivoSeq
Dermatology

Atopic Eczema

65

Pipeline Programs↗

3

Active Trials↗

34

Companies Involved↗

Atopic Eczema is a moderately active landscape with 65 programs across 34 companies. The most active players are Sanofi, Hyundai Pharmaceutical Co., LTD., Johnson & Johnson. 34 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2A

Anacor

1 program

Phase 2S

Sequel Pharmaceuticals, Inc

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

57 of 71 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody1318%Vaccine11%

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 100% of 72 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed11 · 69%
Recruiting2 · 13%
Not yet recruiting1 · 6%
Terminated1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Recruiting·—·Phase 4·NCT06004986·216 enrolled
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
Recruiting·KKing's College London·N/A·NCT05790330·90 enrolled
Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema
Not yet recruiting·JJinnah Postgraduate Medical Centre·Phase 4·NCT07438509·270 enrolled
Protopic Ointment in Adult Atopic Eczema of the Face
Completed·Astellas logoAstellas·Phase 4·NCT00690105·577 enrolled
Prednisolone vs. Ciclosporine in Severe Atopic Eczema
Completed·TTechnische Universität Dresden·Phase 4·NCT00445081·66 enrolled
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
Completed·AAerovance, Inc.·Phase 2·NCT00676884·25 enrolled
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT03822832·51 enrolled
Skin bioMARkers for Atopic Eczema Therapy Evaluation
Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 2·NCT04194814·37 enrolled
Protopic Ointment in Children Atopic Eczema
Completed·Astellas logoAstellas·Phase 4·NCT00689832·487 enrolled
Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema
Completed·—·Phase 2·NCT01119313·20 enrolled
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
Completed·AACO Hud Nordic AB·Phase 3·NCT00576238·55 enrolled
Long-term Safety of Protopic in Atopic Eczema
Completed·Astellas logoAstellas·Phase 3·NCT00560378·789 enrolled
Assessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formulations in Patients With Atopic Eczema; a Phase IIa, Single-center, Randomized, Observer-blind Study
Completed·MMoberg Pharma AB·Phase 1/2·NCT00863005
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Completed·SSterna Biologicals GmbH & Co. KG·Phase 2·NCT02079688·25 enrolled
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
Terminated·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT04086121·14 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)